

Interaction between the endothelium and blood cells in acute coronary syndromes

Giuseppe Ambrosio, Isabella Tritto

Division of Cardiology, University of Perugia School of Medicine, Perugia, Italy

(Ital Heart J 2001; 2 (Suppl 3): 43S-44S)

© 2001 CEPI Srl

This work was partly supported by grant no. 1140 by Comitato Telethon Fondazione Onlus, Rome, Italy, and by grant no. 9906104773_006 by MURST, Rome, Italy.

Address:

Prof. Giuseppe Ambrosio

Divisione di Cardiologia
Università degli Studi
Policlinico Monteluce
Via Brunamonti, 51
06122 Perugia
E-mail:
cardiopg@unipg.it

The introduction of reperfusion strategy in acute coronary syndromes has brought about several new issues. Among others, it has been appreciated that achieving patency of the occluded epicardial vessel may not be sufficient to ensure adequate myocardial perfusion, since significant impairment to flow may occur at the microvascular level. In fact, reperfusion is accompanied by a progressive impairment of blood flow after initial restoration of adequate perfusion, and this phenomenon has thus been termed “no-reflow”¹. Microvascular obstruction is mostly secondary to the “inflammatory” reaction induced in tissues by the postischemic reflow, that results in trapping of neutrophils in the microvasculature, impaired vasodilation, and intravascular activation of platelet aggregation and of coagulation pathway^{1,2}.

Neutrophils are large, stiff cells that normally pass through capillaries because the pressure gradient exceeds the adhesive forces³. During postischemic reperfusion, reduced perfusion pressure and increased neutrophil adhesiveness to the vessel wall favor cell plugging and vascular obstruction. Several mechanisms contribute to alter vasodilating reserve during postischemic reperfusion^{4,5}. First, the presence of a residual coronary stenosis after reperfusion may limit coronary flow reserve. In addition, vasodilation may be impaired by reduced generation of nitric oxide and prostacyclin, while enhanced endothelin formation and damage to vascular β -adrenergic receptors increase vasoconstriction⁴. Reduced nitric oxide production not only impairs vasodilating reserve, but it also stimulates neutrophil and platelet aggregation^{5,6}.

At the same time, other mechanisms promote neutrophil activation and adhesion

to the vessel wall. Postischemic reperfusion induces cytokine production by the endothelium^{7,8}; these molecules can in turn activate neutrophils and the endothelium, with exposure of adhesion molecules on cell surface and increased adherence of these cells to the vessel wall^{8,9}. Adhesion molecules can also be exposed on the surface of cardiac myocytes². Neutrophil activation is also increased by reduced nitric oxide concentrations^{5,6} and increased release of activating mediators, such as the platelet-activating factor, leukotrienes, and complement factors². Activated neutrophils adhere tightly to capillary endothelium, thus mechanically blocking flow. In addition, activated neutrophils and platelets may release vasoconstricting and proinflammatory mediators, further worsening microvascular perfusion².

More recently, it has been appreciated that other pathways may also be involved in the pathogenesis of no-reflow in postischemic hearts. First, cardiac release of angiotensin II may contribute to impair tissue microvascular perfusion during reflow, since this molecule is not only a potent vasoconstrictor, but it might also promote neutrophil recruitment and activation¹⁰⁻¹². Secondly, cardiac mast cells degranulate during myocardial ischemia, releasing preformed mediators, such as histamine and tumor necrosis factor- α , that may play an important role in initiating cytokine release, adhesion molecule exposure and neutrophil recruitment¹³. Finally, the extent of the no-reflow may also be reduced by removal of oxygen radicals, thus suggesting that these molecules are also involved in the pathogenesis of the no-reflow¹⁴. It is not clear through which mechanisms oxygen radicals may influence the no-reflow; however, in addition to their toxic effects, they

may also induce various alterations of cell function which favor vasoconstriction, neutrophil activation and release of proinflammatory mediators^{6,15,16}. Taken together, these various mechanisms integrate to induce neutrophil plugging in the microvasculature, and vascular obstruction in postischemic tissues.

References

1. Ambrosio G, Weisman HF, Mannisi JA, Becker LC. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. *Circulation* 1989; 80: 1846-61.
2. Entman ML, Smith WC. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. *Cardiovasc Res* 1994; 28: 1301-11.
3. Engler RL, Dahlgren MD, Morris D, Peterson MA, Schmidt-Schonbein GW. Role of leukocytes in the response to acute myocardial ischemia and reflow in dogs. *Am J Physiol* 1986; 251: H314-H323.
4. Velasco CE, Turner M, Inagami T, et al. Reperfusion enhances the local release of endothelin after regional myocardial ischemia. *Am Heart J* 1994; 128: 441-51.
5. Ma XL, Weyrich AS, Lefer DM, Lefer AM. Diminished basal nitric oxide release after myocardial ischemia-reperfusion promotes neutrophil adherence to coronary endothelium. *Circ Res* 1993; 72: 403-12.
6. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. *Proc Natl Acad Sci USA* 1991; 88: 4651-5.
7. Yan SF, Tritto I, Pinsky D, et al. Induction of interleukin-6 by hypoxia in vascular cells: central role of the binding site for nuclear factor-IL-6 (NF-IL-6). *J Biol Chem* 1995; 270: 11463-72.
8. Shreeniwas R, Koga S, Karakurum M, et al. Hypoxia-mediated induction of endothelial cell interleukin-1. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. *J Clin Invest* 1992; 90: 2333-9.
9. Yoshida N, Granger DN, Anderson DC, Rothlein R, Lane C, Kvietys PR. Anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. *Am J Physiol* 1992; 262: H1891-H1898.
10. Yamamoto Y, Yamaguchi T, Shimamura M, Hazato T. Angiotensin III is a new chemoattractant for polymorphonuclear leukocytes. *Biochem Biophys Res Commun* 1993; 193: 1038-43.
11. Farber HW, Center DM, Rounds S. Bovine and human endothelial cell production of neutrophil chemoattractant activity in response to components of the angiotensin system. *Circ Res* 1985; 57: 898-902.
12. Grafe M, Auch-Schwelk W, Zakrzewicz A, et al. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. *Circ Res* 1997; 81: 804-11.
13. Frangogiannis NG, Lindsey ML, Michael LH, et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental myocardial ischemia/reperfusion. *Circulation* 1998; 98: 699-710.
14. Villari B, Ambrosio G, Golino P, et al. The effects of calcium channel antagonist treatment and oxygen radical scavenging on infarct size and the no-reflow phenomenon in reperfused hearts. *Am Heart J* 1993; 125: 11-23.
15. Suzuki M, Onauen W, Kvietys PR. Superoxide mediates reperfusion-induced leukocyte-endothelial cell interactions. *Am J Physiol* 1989; 256: H1740-H1745.
16. Petrone WF, English DK, Wong K, McCord JM. Free radicals and inflammation: superoxide-dependent activation of a neutrophil chemotactic factor in plasma. *Proc Natl Acad Sci USA* 1980; 77: 1159-63.